Navigation Links
d’Oliveira & Associates Seeks Clients That Have Been Affected by the Prescription Drug Topamax
Date:3/23/2013

(PRWEB) March 23, 2013

Topamax is a popular anticonvulsant prescription drug manufactured by the Johnson & Johnson subsidiary Ortho-McNeil Pharmaceutical. Originally approved by The U.S. Food and Drug Administration (FDA) in 1996 to treat persons experiencing epileptic seizures, the drug has since been approved as an anti-migraine drug and has thus become a popular drug for both combating epileptic seizures and migraines*. In just 2007 to 2010 alone, nearly 4.3 million patients filled prescriptions to Topamax*. However, in March 2011, the FDA warned that pregnant users of Topamax are at an increased risk that their children will develop birth defects as a result of the drug use*.

Specifically, the FDA's recent study into Topamax revealed that pregnant woman using the migraine and seizure drug exposed their children to an increased risk of developing cleft lip and cleft palate*. Cleft lip is a birth defect where the infant lacks the tissue needed to correctly form the upper lip during pregnancy and results in vertical gaps remaining in the child's lip. Similarly, cleft palate is a birth defect where the child is left with gaps in the back portions and sides of the mouth due to a lack of tissue required for formation during the pregnancy. Both conditions put the child at risk for chronic hearing loss, eating and drinking problems, speech development problems, and even poor overall growth.

In its warning, the FDA has cited a recent study by The Northern American Antiepileptic Drug Pregnancy Registry, which concluded that infants exposed to Topamax (topiramate) during pregnancy are three times more at risk of developing these defects than infants exposed to competing seizure and migraine drugs. According to the study, only 0.38% of infants exposed to other various medications developed the birth defects, whereas 1.4% of the infants exposed specifically to Topamax developed them*. It is important to note that in this study, the percentage of these birth defects in infants whose mothers were exposed to no anticonvulsant medications at all was a mere .07% and that the rate of cleft lip and cleft palate conditions found in infants who mothers took Tapomax was 11 times higher than the national average of children born with those conditions*.

In response to the increased risk of birth defects in pregnant Topamax users, the FDA has called for stronger warnings on the drug's labels and has also changed the drug's pregnancy warning to a Category D, meaning there is positive evidence that the drug poses risks to infants. Director of the FDA's Division of Neurology Products has urged doctors to "carefully consider the benefits and risks of [Topamax] when prescribing it to women of child-bearing age," and to consider "alternative medications" as a preferable option to Topamax.

If you or anyone you know has taken Topamax during a pregnancy, the attorneys at d'Oliveira & Associates urge you to contact them immediately. Working with some of the leading dangerous drug lawyers handling these cases, they want you to know that pregnant users of Topamax are entitled to representation and compensation for any related birth defects.

For a free legal consultation, call 1-800-992-6878 or visit their website at dmlaw.com.

Source:

Read the full story at http://www.prweb.com/releases/2013/3/prweb10548517.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d’Oliveira & Associates Issues Webpage With Current Information On Stryker Hip Implant Lawsuits
2. d’Oliveira & Associates Releases Webpage With Current Information on Fresenius Lawsuits
3. d’Oliveira & Associates Releases Mirena IUD Infographic Describing Bayer’s Deceptive Mirena Simple Style Campaign
4. d’Oliveira & Associates Issues Webpage With Current Information On Mirena IUD Lawsuits
5. d’Oliveira & Associates Releases New Webpage on Pradaxa Lawsuits
6. D’Oliveira & Associates Helps Woonsocket, RI Man Receive Over $38,000 in Back Due Benefits
7. Research shows efficacy of treatment model developed at Women & Infants
8. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
9. Vendors in Nevada, Michigan, & Illinois to be Featured on the PartyPOP.com Online Network
10. Beef & Pork Wholesaling in the US Industry Market Research Report Now Available from IBISWorld
11. The Tennessee Car Accident Lawyers at Michael D. Ponce & Associates Alert Public of CDC Survey Revealing Majority of High School Seniors Admitting to Texting Behind Wheel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
Breaking Medicine Technology: